Other phase I and phase II studies have confirmed these antitumor effects of DEX and MAGE-3 on advanced non-small cell lung cancer patients[13, 14]; ascites-derived EVs combined with granulocyte–macrophage colony-stimulating factor (GM-CSF) on colorectal cancer[15]; tumor cell-derived EVs packed with methotrexate in lung cancer [16]; and even plant-derived EVs loaded with curcumin in colon cancer (NCT01294072) [17]. The gene discussed is MAGEA3; the disease is neoplasm.